Abstract
Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 enzyme superfamily with responsibility for metabolizing many important exogenous and endogenous compounds in many species of microorganisms, plants and animals. CYP2C9 is related to the oxidative of 16% of all therapeutics in current clinical use and has adverse drug effects, such as, enzyme induction and inhibition. In order to understand the metabolic mechanism of various drugs, two crystal structures of CYP2C9 have been studied, and their structural differences and structure-activity relationships with the drugs of Fluoxetine, Ibuprofen, Naproxen, Suprofen, and Mefenamic acid were investigated. By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
Keywords: CYP2C9, cytochrome P-450, structure-activity relationship, metabolic mechanism
Medicinal Chemistry
Title: Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism
Volume: 5 Issue: 3
Author(s): Jing-Fang Wang, Jing-Yi Yan, Dong-Qing Wei and Kuo-Chen Chou
Affiliation:
Keywords: CYP2C9, cytochrome P-450, structure-activity relationship, metabolic mechanism
Abstract: Cytochrome P450 2C9 (CYP2C9) is an important member of the cytochrome P450 enzyme superfamily with responsibility for metabolizing many important exogenous and endogenous compounds in many species of microorganisms, plants and animals. CYP2C9 is related to the oxidative of 16% of all therapeutics in current clinical use and has adverse drug effects, such as, enzyme induction and inhibition. In order to understand the metabolic mechanism of various drugs, two crystal structures of CYP2C9 have been studied, and their structural differences and structure-activity relationships with the drugs of Fluoxetine, Ibuprofen, Naproxen, Suprofen, and Mefenamic acid were investigated. By a series of docking studies and MD simulations, the binding pockets of CYP2C9 for the five drugs are explicitly defined that will be very useful for conducting mutagenesis studies, providing insights into the metabolic mechanism, which may be of relevance to the personalized drug.
Export Options
About this article
Cite this article as:
Wang Jing-Fang, Yan Jing-Yi, Wei Dong-Qing and Chou Kuo-Chen, Binding of CYP2C9 with Diverse Drugs and its Implications for Metabolic Mechanism, Medicinal Chemistry 2009; 5 (3) . https://dx.doi.org/10.2174/157340609788185954
| DOI https://dx.doi.org/10.2174/157340609788185954 |
Print ISSN 1573-4064 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Medicinal Chemistry Metabolic Activation of Herbal and Dietary Constituents and Its Clinical and Toxicological Implications: An Update
Current Drug Metabolism Myositis Associated with the Anti-COVID-19 Covishield Vaccine
Current Respiratory Medicine Reviews Current Synthetic Approaches to Peptide and Peptidomimetic Cyclization
Current Organic Chemistry Pharmacological Management of PDA: Oral Versus Intravenous Medications
Current Clinical Pharmacology Microwave-assisted Synthesis of Pharmacologically Active 4-Phenoxyquinolines and their Benzazole-quinoline Hybrids Through S<sub>N</sub>Ar Reaction of 4,7-dichloroquinoline and Phenols Using [bmim][PF<sub>6</sub>] as a Green Solvent
Current Organic Synthesis Recent Development in the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors for Non-small Cell Lung Cancer
Current Medicinal Chemistry Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Therapeutic Applications of Fucoidans and their Potential to Act Against COVID-19
Current Pharmaceutical Design The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19
Current Pharmaceutical Design Differentiation Between Osteoporotic and Neoplastic Vertebral Fractures: State of The Art and Future Perspectives
Current Medical Imaging Chagas Disease: Progress and New Perspectives
Current Medicinal Chemistry Global Gene Expression in Classification, Pathogenetic Understanding and Identification of Therapeutic Targets in Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Benzenecarboxamide Analogs of Fluoroquinolones (BCFQs). Antibacterial Activity and SAR Studies
Letters in Drug Design & Discovery Review of QSAR for DNA Polymerase Inhibitors and New Models for Heterogeneous Series of Compounds
Current Computer-Aided Drug Design The Role of Coagulation in Pulmonary Pathology
Inflammation & Allergy - Drug Targets (Discontinued) Phenyldihydroxypyrimidines as HCV NS5B RNA Dependent RNA Polymerase Inhibitors. Part II: Sulfonamides
Letters in Drug Design & Discovery Metabolic Syndrome, Alzheimer’s Disease, and Covid 19: A Possible Correlation
Current Alzheimer Research Meet the Editorial Board Member
Current HIV Research 1,4-Dihydropyridine Scaffold in Medicinal Chemistry, The Story so Far And Perspectives (Part 1): Action in Ion Channels and GPCRs
Current Medicinal Chemistry





